이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes (ALCO1)

2017년 7월 20일 업데이트: Ajenthen Ranjan, Hvidovre University Hospital

Objective: Because many people with type 1 diabetes drink ethanol and because glucagon is used to treat mild hypoglycaemia, it is essential to determine whether ethanol will impair the effectiveness of glucagon to increase glucose, which may impair the effectiveness of the dual hormone treatment in preventing hypoglycaemia.

The purpose of this study is to determine, whether ethanol influences the glucose response to subcutaneous glucagon during mild hypoglycaemia.

The investigators hypothesize that prior evening ethanol consumption does not reduce the effect of a glucagon bolus to raise plasma glucose compared with no prior ethanol consumption.

The study aims:

  1. To determine the late effects of ethanol on the efficacy of subcutaneous glucagon to restore plasma glucose after an episode of mild hypoglycemia.
  2. To determine the late effects of ethanol on the counter-regulatory hormones and hypoglycaemia awareness during mild hypoglycaemia

A double-blinded placebo-controlled study will be conducted. Participants will serve as their own controls. Eligible participants will after an informed consent complete two study visits, one with and one without ethanol consumption, in a random order. On each study visit, participants are induced a insulin induced hypoglycemia, seven-eight hours after a meal with or without ethanol. Once plasma glucose is below 3.9 mmol/l, a subcutaneous injection of 100 mcg glucagon is administered. Two hours later a second bolus is administered.

연구 개요

연구 유형

중재적

등록 (실제)

12

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Hvidovre, 덴마크, 2650
        • Hvidovre University Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age 18 - 70 years
  • T1D ≥ 3 year
  • BMI 20-28 kg/m2
  • CSII ≥ 1 year
  • Caucasian origin
  • Hypoglycaemia awareness (assessed by Gold, Clarke and Pedersen-Bjergaard methods)
  • Use of carbohydrate counting and the insulin pump bolus calculator for all meals
  • Ethanol exposure once within 1 year consisting of at least 4 drinks (1 drink contains 12 gram ethanol) within four hours

Exclusion Criteria:

  • Allergy or intolerance to lactose or Glucagen®(Novo Nordisk, Bagsværd, DK)
  • Allergy for ethanol or any food ingredients that will be used in the study.
  • Impaired renal function (eGFR < 60 ml/min/1.73m2)
  • Liver disease with ALAT > 2.5 times the upper limit of the reference interval
  • Gastropareses (beat-beat variation < 10 beats per min and/or orthostatic systolic blood pressure > 20 mmHg)
  • Insomnia, sleep apnoea or any troubles with sleeping that according to the investigator's assessment makes the individual unsuitable for study participation.
  • Aldehyde dehydrogenase deficiency as determined by a screening questionnaire
  • Unable to refrain from the consumption of ethanol at least 24 hours prior to study start
  • History of drinking problems or alcoholism, regardless of whether active or in remission.
  • Use of benzodiazepines or barbiturates or opiates or other central nervous system depressant drugs that could act synergistically with ethanol to lower the level of consciousness
  • History of drug abuse
  • Current participation in another diabetes-related clinical trial that, in the judgment of the principle investigator, will compromise the results of the study or the safety of the subject.
  • Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
  • Use of medications that are known to cause QT interval prolongation
  • Presence of pheochromocytoma
  • Other concomitant medical or psychological condition that according to the investigator's assessment makes the individual unsuitable for study participation
  • Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.
  • Females who have different basal insulin pattern depending on their menstrual cycle.
  • Inability to understand the individual information and to give informed consent.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Ethanol
Drinking a cocktail of ethanol (0.8 g ethanol per kg body weight), diet lemonade and water of 1:1:1 (volume distribution).
다른 이름들:
  • 칵테일
위약 비교기: Non-ethanol
Drinking a cocktail of diet lemonade and water of 1:2 (volume distribution).
다른 이름들:
  • 칵테일

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Increase in plasma glucose
기간: 0-120 min after the first glucagon injection
The primary endpoint is difference in increase in plasma glucose value after the first injection of 100 µg s.c. glucagon on study nights with ethanol vs. study nights without ethanol consumption.
0-120 min after the first glucagon injection

2차 결과 측정

결과 측정
측정값 설명
기간
Peak plasma glucose
기간: 0-240 min after the first glucagon injection
Maximal plasma glucose after the first and second glucagon injection
0-240 min after the first glucagon injection
Increase in plasma glucose
기간: 0-120 min after the second glucagon injection
Increase in plasma glucose caused by the second glucagon injection.
0-120 min after the second glucagon injection
Total AUC(0-120)
기간: 0-240 min after the first glucagon injection
Total area under the glucose curve from 0-120 minutes after each glucagon injection
0-240 min after the first glucagon injection
PI-AUC(0-120)
기간: 0-240 min after the first glucagon injection
positive incremental area under the glucose curve from 0-120 minutes after each glucagon injection
0-240 min after the first glucagon injection
Tmax
기간: 0-240 min after the first glucagon injection
Time-to-peak glucose value after each glucagon injection glucagon injection
0-240 min after the first glucagon injection
Time above 4.0mM
기간: 0-240 min after the first glucagon injection
Duration of glucose above 4.0 mmol/l after first and second glucagon injection
0-240 min after the first glucagon injection
Time above baseline
기간: 0-240 min after the first glucagon injection
Duration of glucose above baseline after first and second glucagon injection
0-240 min after the first glucagon injection
Rescue rates
기간: 0-240 min after the first glucagon injection
Numbers of first and second glucagon injections that raises PG > 4.9 mmol/l
0-240 min after the first glucagon injection
Hyperglycemia rates
기간: 0-240 min after the first glucagon injection
Number of first and second glucagon injections that raises PG > 7.1 mmol/l
0-240 min after the first glucagon injection
Changes in plasma ketone bodies, measured as area under the curve
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in plasma ketone bodies, measured as incremental peak
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in plasma glucagon, measured as area under the curve
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in plasma glucagon, measured as incremental peak
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in insulin, measured as area under the curve
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in insulin, measured as incremental peak
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in growth hormones, measured as area under the curve
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in growth hormones, measured as incremental peak
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in serum corticole, measured as area under the curve
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in serum corticole, measured as incremental peak
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in plasma ethanol, measured as area under the curve
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in plasma ethanol, measured as incremental peak
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in free fatty acids, measured as area under the curve
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in free fatty acids, measured as incremental peak
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in triglycerides, measured as area under the curve
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Changes in triglycerides, measured as incremental peak
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Average in blood pressure
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Average heart rate
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Intensity of hypoglycemia
기간: 0-240 min after the first glucagon injection
Average changes in Edinburgh Hypoglycaemia Scale over time during insulin and glucagon phase
0-240 min after the first glucagon injection
Cognitive impairment
기간: 0-240 min after the first glucagon injection
Average scores in cognitive test 30 min before each glucagon injection.
0-240 min after the first glucagon injection
Side effects
기간: 0-240 min after the first glucagon injection
Average visual analogue scale score from 0-180 min for nausea and headache after glucagon injection
0-240 min after the first glucagon injection
Incidence of vomiting
기간: 0-240 min after the first glucagon injection
Incidence of vomiting after 0-4 hours after each glucagon injection.
0-240 min after the first glucagon injection
Meal induced glucose excursion
기간: 0-3 hours after meal
Total and incremental area under the glucose curve from 0-120 and 0-240 min after eating the mixed meal
0-3 hours after meal
Meal induced hormonal changes
기간: 0-3 hours after meal
Total and incremental area under the glucose curve from 0-120 and 0-240 min after eating the mixed meal
0-3 hours after meal
Nocturnal changes in plasma glucose
기간: 0-6 hours after start of sleep
Area under the curve during sleep
0-6 hours after start of sleep
Nocturnal changes in corticol
기간: 0-6 hours after start of sleep
Area under the curve during sleep
0-6 hours after start of sleep
Nocturnal changes in growth hormone
기간: 0-6 hours after start of sleep
Area under the curve during sleep
0-6 hours after start of sleep
Nocturnal changes in ketones
기간: 0-6 hours after start of sleep
Area under the curve during sleep
0-6 hours after start of sleep
Nocturnal changes in ethanol
기간: 0-6 hours after start of sleep
Area under the curve during sleep
0-6 hours after start of sleep
Nocturnal changes in glucagon
기간: 0-6 hours after start of sleep
Area under the curve during sleep
0-6 hours after start of sleep
Difference between the first second glucagon injection and between both study visits in peak change plasma glucose
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Difference between glucagon injections on both study visits in positive incremental area under the glucose curve from 0-120 minutes
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Difference between glucagon injections on both study visits in total area under the glucose curve from 0-120 minutes
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Difference between glucagon injections on both study visits in time-to-peak glucose value
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Difference between glucagon injections on both study visits in duration of glucose above 4.0 mmol/l after first and second glucagon injection
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Difference between glucagon injections on both study visits in duration of glucose above baseline after first and second glucagon injection
기간: 0-240 min after the first glucagon injection
0-240 min after the first glucagon injection
Difference in glucose sensor data on study night with alcohol vs. study night without alcohol - Mean absolute relative difference (MARD) values of glucose sensors compared with YSI from 7 PM- 8 AM.
기간: 0-10 hours after meal
Intentions to treat analysis
0-10 hours after meal
Difference in glucose sensor data on study night with alcohol vs. study night without alcohol - Precision absolute relative difference (PARD) 120 min before and 120 after each glucagon injection.
기간: 0-10 hours after meal
Intentions to treat analysis
0-10 hours after meal
Difference in glucose sensor data on study night with alcohol vs. study night without alcohol - MARD values between glucose sensors 0-120 minutes after each glucagon injection.
기간: 0-10 hours after meal
Intentions to treat analysis
0-10 hours after meal
Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Time in range (glucose sensor value =4.0-10.0mmol/l)
기간: 0-2 days after the first glucagon injection
Intentions to treat analysis
0-2 days after the first glucagon injection
Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Time in hypoglycaemia (glucose sensor value < 4.0 mmol/l)
기간: 0-2 days after the first glucagon injection
Intentions to treat analysis
0-2 days after the first glucagon injection
Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Time in hyperglycaemia (glucose sensor value >10.0mmol/l)
기간: 0-2 days after the first glucagon injection
Intentions to treat analysis
0-2 days after the first glucagon injection
Difference in glucose sensor data within 2 days after study night with alcohol vs. study night without alcohol - Number of hypoglycaemia episodes (glucose sensor value < 4.0 mmol/l)
기간: 0-2 days after the first glucagon injection
Intentions to treat analysis
0-2 days after the first glucagon injection
Difference in glucose sensor data between the study period with and without alcohol - Clarke- Error Grid analysis for both sensors compared with YSI during study visit
기간: -2 to 4 days after study visits
Intentions to treat analysis
-2 to 4 days after study visits
Difference in glucose sensor data between the study period with and without alcohol - PARD values from day 1-7
기간: -2 to 4 days after study visits
Intentions to treat analysis
-2 to 4 days after study visits
Difference in glucose sensor data between the study period with and without alcohol - PARD values <4.0 mmol/L from day 1-7
기간: -2 to 4 days after study visits
Intentions to treat analysis
-2 to 4 days after study visits
Difference in glucose sensor data between the study period with and without alcohol - PARD values 4.0-10.0 mmol/L from day 1-7
기간: -2 to 4 days after study visits
Intentions to treat analysis
-2 to 4 days after study visits
Difference in glucose sensor data between the study period with and without alcohol PARD values >10.0 mmol/L from day 1-7
기간: -2 to 4 days after study visits
Intentions to treat analysis
-2 to 4 days after study visits
Difference in glucose sensor data between the study period with and without alcohol - Number of hypoglycaemia episodes (glucose sensor value < 4.0 mmol/l)
기간: -2 to 4 days after study visits
Intentions to treat analysis
-2 to 4 days after study visits

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Ajenthen Ranjan, MD, Hvidovre University Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2016년 8월 1일

기본 완료 (실제)

2017년 1월 26일

연구 완료 (실제)

2017년 1월 26일

연구 등록 날짜

최초 제출

2016년 8월 11일

QC 기준을 충족하는 최초 제출

2016년 8월 23일

처음 게시됨 (추정)

2016년 8월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 7월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 7월 20일

마지막으로 확인됨

2017년 7월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

위약에 대한 임상 시험

3
구독하다